Abstract:Background The high‐fat, low carbohydrate ketogenic diet (KD) is a proven therapy for patients with medically refractory epilepsy. The metabolic changes induced by the KD mimics the physiological alteration of fasting and calorie restriction – wherein ketone levels are elevated (ketosis). Both the KD and its metabolic substrates are involved in modulating anti‐seizure effects, but the molecular target of these beneficial effects have yet to be fully elucidated. One potential molecular explanation links the mammalian target of rapamycin (mTOR) signaling pathway. Disruptions in the mTOR pathway may explain in part susceptibility to and pathogenesis of epilepsy. The primary purpose of this study was to investigate the role of metabolic changes in mTOR signaling pathway in the Kcna1‐null mouse model of epilepsy and whether its mechanistic effects are linearly correlated with ketosis. Methods Spontaneously epileptic Kcna1‐null (KO) mice were generated using heterozygous breeding pairs. At P21‐ 23, mice were treated with the KD and either standard diet (SD) or SD with subcutaneous administration of BHB through osmotic mini‐pumps for 2–3 weeks. Blood from tail clippings were used to measure BHB and glucose levels. EEG electrodes were implanted through parasaggital burr holes in either wild type (WT) mice or KO mice around P28. Following a 3‐day recovery period, seizure activity was assessed over 72 continuous hours. After over 2 weeks of treatment, hippocampal lysates were collected from: (1) SD‐fed WT; (2) SD‐fed KO; (3) KD‐fed WT; (4) KD‐fed KO; (5) saline‐treated WT; (6) saline‐treated KO; (7) BHB‐treated WT; and (8) BHB–treated KO mice. Samples were probed with antibodies against upstream modulators of mTOR, either phosphorylated ‐ or total –AMPK, and downstream effectors of mTOR, phospho‐ or total ‐ S6, as well as a downstream effectors of AMPK, either glial fibrillary acidic protein (GFAP) or Tubulin. Total RNA obtained from hippocampus or whole brain using TRIzol was reverse transcribed into cDNA by RT‐PCR and then the single‐stranded cDNA was amplified by PCR with primers for GFAP and β‐actin. Results Using western blot analysis, mTOR signaling was significantly increased in KO mice accompanied with spontaneous epileptic discharge, and levels of upstream pAMPK were decreased in these animals compared to control and KD‐fed KO mice. KO mice showed a significant enhancement in the downstream markers pS6 and p4EBP1, whereas this effect was strongly suppressed by the KD treatment. KD treatment led to a reduction in pS6 in kainic acid (KA)‐treated control mice. KA resulted in a gradual increase of GFAP. In contrast, at 24 hours post KA injection, KD‐fed mice exhibited a significant decrease in expression level of GFAP. Conclusion Collectively, either the KD or ketone not only reduces the severity of seizures in two different mouse models, but also attenuates mTOR signaling pathways. Further, our finding that phospho‐S6 is reduced by KD treatment suggests a mechanistic link between mTOR inhibition and decreases in astrogliosis, both mechanisms that could contribute to the anti‐seizure and neuroprotective effects of the KD. The results provide evidence for the functional protective link between the KD and its primary metabolic substrate, β‐hydroxybutyrate, in spontaneously epileptic Kcna1‐null mice. Finally, the therapeutic effects of BHB and the KD may be in part inhibitory action of glial cell activation through modulation of mTOR signaling pathway Effects of the ketogenic diet on seizure‐evoked upregulation of mTOR signaling pathways in the hippocampus of Kcna1‐null mice. (A & D)

Reduction of epileptiform activity in ketogenic mice: The role of monocarboxylate transporters

The Ketogenic Diet Attenuates Both Hyperactivity in mTOR pathway and Astrogliosis Through Regulation of AMPK signaling in the Epileptic Brain

Ketogenic diet-produced β-hydroxybutyric acid accumulates brain GABA and increases GABA/glutamate ratio to inhibit epilepsy

A Ketogenic Diet Affects Gut Microbiota by Regulating Gut Microbiota and Promoting Hippocampal TRHR Expression to Combat Seizures

Effective reduction in seizure severity and prevention of a fatty liver by a novel low ratio ketogenic diet composition in the rapid kindling rat model of epileptogenesis

Effectiveness of Ketogenic Diet in Pentylenetetrazol-Induced and Kindling Rats As Well As Its Potential Mechanisms.

Ketogenic Diet Alleviates Hippocampal Neurodegeneration Possibly Via ASIC1a and the Mitochondria-Mediated Apoptotic Pathway in a Rat Model of Temporal Lobe Epilepsy

A ketogenic diet modifies glutamate, gamma-aminobutyric acid and agmatine levels in the hippocampus of rats: A microdialysis study

MRI spectroscopic and tractography studies indicate consequences of long-term ketogenic diet

Metabolic Therapy for Temporal Lobe Epilepsy in a Dish: Investigating Mechanisms of Ketogenic Diet using Electrophysiological Recordings in Hippocampal Slices

Metabolic fingerprinting of dogs with idiopathic epilepsy receiving a ketogenic medium-chain triglyceride (MCT) oil

Ketogenic Diet Provided During Three Months Increases KCC2 Expression but Not NKCC1 in the Rat Dentate Gyrus

Simplification of Dietary Treatment in Pharmacoresistant Epilepsy: Impact of C8 and C10 Fatty Acids on Sirtuins of Neuronal Cells In Vitro

Mechanism of Action of Ketogenic Diet Treatment: Impact of Decanoic Acid and Beta—Hydroxybutyrate on Sirtuins and Energy Metabolism in Hippocampal Murine Neurons

Exogenous ketones exert antiseizure effects and modulate the gut microbiome and mycobiome in a clinically relevant murine model of epilepsy

The possible antioxidative effects of ketogenic diet by modifying brain klotho expression: a rat model study

Effects of ketogenic diet on the classification and functional composition of intestinal flora in children with mitochondrial epilepsy

Progress of the Antiepileptic Mechanisms of Ketogenic Diet

The Ketogenic Diet for the Treatment of Epilepsy: A Challenge for Nutritional Neuroscientists

A ketogenic diet affects brain volume and metabolome in juvenile mice

Metabolic epilepsies amenable to ketogenic therapies: Indications, contraindications, and underlying mechanisms